Beam Therapeutics Inc
Q3 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +1.55%.
Did BEAM Beat Earnings? Q3 2025 Results
Beam Therapeutics delivered a disappointing third quarter, missing on both top and bottom lines as heavier research spending weighed on results. The clinical-stage base editing company posted a loss of $1.10 per share, coming in 7.10% below the consensus estimate of $1.03, while revenue fell to $9.70 million, a 23.79% shortfall versus the $12.72 million analysts had expected and a steep 32.0% decline from the $14.27 million recorded a year ago. The primary culprit was a surge in R&D expenses to $109.77 million, including $14.50 million in in-process R&D tied to an acquisition completed during the quarter, widening the net loss to $112.73 million. Still, the narrative is not entirely downbeat; Beam ended September with roughly $1.1 billion in cash, extending its runway into 2028, and investor attention is increasingly focused on pipeline catalysts, including updated BEAM-302 Phase 1/2 data expected in early 2026 and BEAM-101 sickle cell results set for presentation at the ASH Annual Meeting in December 2025, with potential proceeds from Bristol Myers Squibb's $1.50 billion acquisition of Orbital Therapeutics adding another variable to the outlook.
- Increased R&D spending driven by clinical trial advancement and $14.5 million in-process R&D from acquisition
- Interest and other income of $10.9 million partially offsetting operating losses
- Higher share count (102.6 million vs 82.4 million) contributing to improved per-share loss despite wider absolute net loss
“As we near the end of 2025, we see broad-based momentum across our growing portfolio of clinical-stage hematology and liver-targeted genetic disease base editing programs. Our alpha-1 antitrypsin deficiency program, the first clinical program to directly correct a disease-causing mutation in vivo, remains a top priority, and we're pleased with the continued enrollment and dosing progress in the BEAM-302 Phase 1/2 trial. We look forward to providing a broad update on the program in early 2026 with new clinical data and next steps to advance BEAM-302 to patients. In sickle cell disease, we look forward to sharing updated data from the BEACON trial of BEAM-101 at the ASH meeting in December, where we aim to continue to demonstrate a differentiated manufacturing and clinical profile in these patients with recurrent severe VOCs. We have also initiated dosing of the BEAM-103 antibody from our ESCAPE platform, which we believe can play an important role in next wave therapies for sickle cell disease.”
Beam Therapeutics CEO, on the earnings call
Forward Guidance & Outlook
Beam expects its cash, cash equivalents and marketable securities of approximately $1.1 billion as of September 30, 2025 to fund anticipated operating expenses and capital expenditure requirements into 2028. Key upcoming milestones include: updated BEAM-302 Phase 1/2 data and a clinical development update in early 2026; continued dosing in the BEAM-301 Phase 1/2 trial for GSDIa; and updated BEACON trial data for BEAM-101 to be presented at the ASH Annual Meeting in December 2025. The company also anticipates potential proceeds from Bristol Myers Squibb's $1.5 billion acquisition of Orbital Therapeutics, in which Beam holds approximately 17% fully diluted ownership.
BEAM YoY Financials
Figures from SEC filings and company reports. Not investment advice.